Inside BENEO’s new pulse plant: pioneering sustainable protein from faba beans
Paving the evidences for the earlier clinical studies of CurQfen
In a first of its kind of studies, a group of cancer biology researchers from Indian Institute of Technology (IIT)- Guwahati lead by Prof. Ajaikumar Kunnumekkara reported the molecular evidence for the remarkable ability of CurQfen-curcumin to modulate the genes responsible for various chronic diseases indicating its effectiveness as prophylaxis.
Many interesting observations were made in this study; say, the genes which significantly upregulate during various cancer types got down regulated and vice versa. Similarly, many of the genes differentially expressed in various chronic inflammatory conditions, obesity, cardiovascular diseases and liver steatosis were also modulated by the treatment of CurQfen. Therefore, the results shed light on the protective role of CurQfen in the prevention and treatment of multiple chronic diseases and paved the evidences for the earlier clinical studies of CurQfen.
“We are inspired by the encouraging results of the global gene expression by RNA Seq analysis in an inflammatory environment and would like to conduct more studies to bring out the full potential of CurQfen as a prophylactic agent, especially against chronic diseases. Nutraceuticals better fit for the fact ‘Prevention is better than Cure’ and CurQfen shows tremendous opportunity”, said Emmanuel Nambusseril, Chief Marketing Officer, Akay Natural Ingredients, manufacturers of CurQfen, which recently was awarded as the ingredient of the year 2021 for cognitive function by NutraIngredients Asia.